WallStSmart

Accendra Health Inc (ACH)vsHong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Accendra Health Inc generates 16501% more annual revenue ($2.72B vs $16.36M). HKPD leads profitability with a -4.3% profit margin vs -39.8%. ACH earns a higher WallStSmart Score of 44/100 (D).

ACH

Hold

44

out of 100

Grade: D

Growth: 2.7Profit: 2.5Value: 7.7Quality: 4.5
Piotroski: 2/9Altman Z: 0.52

HKPD

Avoid

27

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 3/9Altman Z: 3.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACHUndervalued (+71.5%)

Margin of Safety

+71.5%

Fair Value

$8.34

Current Price

$2.70

$5.64 discount

UndervaluedFair: $8.34Overvalued

Intrinsic value data unavailable for HKPD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACH2 strengths · Avg: 9.0/10
Debt/EquityHealth
-4.6710/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.708/10

Growing faster than its price suggests

HKPD2 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
3.8410/10

Safe zone — low bankruptcy risk

Areas to Watch

ACH4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$255.02M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-198.4%2/10

ROE of -198.4% — below average capital efficiency

HKPD4 concerns · Avg: 2.8/10
Market CapQuality
$9.28M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.0%3/10

Operating margin of 3.0%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ACH

The strongest argument for ACH centers on Debt/Equity, PEG Ratio. PEG of 0.70 suggests the stock is reasonably priced for its growth.

Bull Case : HKPD

The strongest argument for HKPD centers on Price/Book, Altman Z-Score.

Bear Case : ACH

The primary concerns for ACH are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : HKPD

The primary concerns for HKPD are Market Cap, Operating Margin, Piotroski F-Score.

Key Dynamics to Monitor

ACH is growing revenue faster at -6.8% — sustainability is the question.

HKPD generates stronger free cash flow (-106,393), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ACH scores higher overall (44/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accendra Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Aluminum Corporation of China Limited, manufactures and sells alumina, primary aluminum and energy products in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.

Want to dig deeper into these stocks?